You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, April 2014
|
| DOI | 10.1186/2051-1426-2-7 |
| Pubmed ID | |
| Authors |
David A Schaer, Daniel Hirschhorn-Cymerman, Jedd D Wolchok |
| Abstract |
With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of the tumor necrosis factor receptor (TNFR) family. Agonist antibodies to these co-stimulatory molecules target both T and B cells, modulating T-cell activation and enhancing immune responses. In vitro and in vivo preclinical data have provided the basis for continued development of 4-1BB, OX40, glucocorticoid-induced TNFR-related gene, herpes virus entry mediator, and CD27 as potential therapies for patients with cancer. In this review, we summarize the immune response to tumors, consider preclinical and early clinical data on select TNFR family members, discuss potential translational challenges and suggest possible combination therapies with the aim of inducing durable antitumor responses. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 177 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 2% |
| France | 1 | <1% |
| Netherlands | 1 | <1% |
| United Kingdom | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 170 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 55 | 31% |
| Student > Ph. D. Student | 26 | 15% |
| Other | 15 | 8% |
| Student > Bachelor | 15 | 8% |
| Student > Master | 13 | 7% |
| Other | 33 | 19% |
| Unknown | 20 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 56 | 32% |
| Medicine and Dentistry | 32 | 18% |
| Immunology and Microbiology | 26 | 15% |
| Biochemistry, Genetics and Molecular Biology | 19 | 11% |
| Chemistry | 4 | 2% |
| Other | 16 | 9% |
| Unknown | 24 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2020.
All research outputs
#4,369,982
of 25,374,917 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,153
of 3,421 outputs
Outputs of similar age
#41,052
of 239,871 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 18 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,871 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.